CY1123307T1 - Πρωτεϊνες συγχωνευσης fgf21 μακρας δρασης και φαρμακευτικες συνθεσεις που τις περιλαμβανουν - Google Patents

Πρωτεϊνες συγχωνευσης fgf21 μακρας δρασης και φαρμακευτικες συνθεσεις που τις περιλαμβανουν

Info

Publication number
CY1123307T1
CY1123307T1 CY20201100796T CY201100796T CY1123307T1 CY 1123307 T1 CY1123307 T1 CY 1123307T1 CY 20201100796 T CY20201100796 T CY 20201100796T CY 201100796 T CY201100796 T CY 201100796T CY 1123307 T1 CY1123307 T1 CY 1123307T1
Authority
CY
Cyprus
Prior art keywords
long
pharmaceutical compositions
fusion proteins
compositions containing
fusion protein
Prior art date
Application number
CY20201100796T
Other languages
English (en)
Inventor
Jun Hwan Kim
Seyoung LIM
Minji Seo
Hyun Ho Choi
Dohoon Kim
Mi Kyeong Ju
Ju-Young Park
Byung Hyun Choi
Jun Kyung Lee
Jong Gyun Kim
Su Youn NAM
Original Assignee
Yuhan Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020150150574A external-priority patent/KR102668200B1/ko
Application filed by Yuhan Corporation filed Critical Yuhan Corporation
Publication of CY1123307T1 publication Critical patent/CY1123307T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μία πρωτεΐνη συγχώνευσης που περιλαμβάνει μία μεταλλαγμένη πρωτεΐνη FGF21 και μία περιοχή Fc μίας ανοσοσφαιρίνης. Η πρωτεΐνη συγχώνευσης, σύμφωνα με την παρούσα εφεύρεση, εκδηλώνει βελτιωμένη φαρμακολογική δραστικότητα, διάρκεια in vivo και σταθερότητα πρωτεΐνης και μία φαρμακευτική σύνθεση, που περιλαμβάνει την πρωτεΐνη συγχώνευσης ως δραστικό συστατικό, μπορεί να χρησιμοποιηθεί αποτελεσματικά ως θεραπευτικός παράγοντας για τον διαβήτη, την παχυσαρκία, τη δυσλιπιδαιμία, το μεταβολικό σύνδρομο, τη μη αλκοολική λιπώδη νόσο του ήπατος ή τη μη αλκοολική στεατοηπατίτιδα.
CY20201100796T 2015-10-28 2020-08-26 Πρωτεϊνες συγχωνευσης fgf21 μακρας δρασης και φαρμακευτικες συνθεσεις που τις περιλαμβανουν CY1123307T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150150574A KR102668200B1 (ko) 2015-10-28 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
PCT/KR2016/012288 WO2017074117A1 (en) 2015-10-28 2016-10-28 Long-acting fgf21 fusion proteins and pharmaceutical composition comprising same

Publications (1)

Publication Number Publication Date
CY1123307T1 true CY1123307T1 (el) 2021-12-31

Family

ID=58630685

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100796T CY1123307T1 (el) 2015-10-28 2020-08-26 Πρωτεϊνες συγχωνευσης fgf21 μακρας δρασης και φαρμακευτικες συνθεσεις που τις περιλαμβανουν

Country Status (21)

Country Link
US (2) US11142557B2 (el)
EP (2) EP3368554B1 (el)
JP (2) JP7303629B2 (el)
CN (1) CN108290937B (el)
AU (2) AU2016346864B2 (el)
BR (1) BR112018008676A2 (el)
CA (1) CA3003109A1 (el)
CY (1) CY1123307T1 (el)
DK (1) DK3368554T3 (el)
ES (1) ES2815540T3 (el)
HK (1) HK1257375A1 (el)
HR (1) HRP20201392T1 (el)
HU (1) HUE051036T2 (el)
LT (1) LT3368554T (el)
MX (1) MX2018005194A (el)
PT (1) PT3368554T (el)
RS (1) RS60725B1 (el)
RU (1) RU2741087C2 (el)
SI (1) SI3368554T1 (el)
WO (1) WO2017074117A1 (el)
ZA (1) ZA201802002B (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3368554T1 (sl) 2015-10-28 2020-10-30 Yuhan Corporation Dolgo-delujoči FGF21 fuzijski proteini in farmacevtski sestavek, ki obsega le-te
RU2741345C2 (ru) * 2015-10-28 2021-01-25 Юхан Корпорейшн Белки с двойной функцией и содержащая их фармацевтическая композиция
AU2017358289A1 (en) * 2016-11-10 2019-06-20 Yuhan Corporation Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
JP7191850B2 (ja) 2017-04-21 2022-12-19 ユーハン・コーポレイション デュアル機能タンパク質およびその誘導体を生産するための方法
JP2020533304A (ja) * 2017-09-08 2020-11-19 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改変型線維芽細胞成長因子２１（ｆｇｆ−２１）を用いる非アルコール性脂肪性肝炎（ｎａｓｈ）の処置方法
JP2021528422A (ja) * 2018-06-21 2021-10-21 サノフイＳａｎｏｆｉ 最適化された活性比を有するｆｇｆ２１化合物／ｇｌｐ−１ｒアゴニストの組合せ
CN108635571B (zh) * 2018-07-19 2021-10-22 西安交通大学医学院第一附属医院 鸢尾素(irisin)在制备预防及治疗重症急性胰腺炎药物中的应用
CN111195234B (zh) * 2018-11-16 2022-08-26 鲁南制药集团股份有限公司 一种重组FGF21-Fc融合蛋白冻干粉制剂
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
KR20210137093A (ko) * 2019-03-05 2021-11-17 선샤인 레이크 파르마 컴퍼니 리미티드 폴리펩티드 분자 및 이의 적용
AU2020260931B2 (en) * 2019-04-23 2023-08-24 Lg Chem, Ltd. Fusion polypeptide comprising Fc region of immunoglobulin and GDF15
US20230090114A1 (en) * 2020-01-31 2023-03-23 89Bio Ltd. Methods for promoting weight loss
US20240165202A1 (en) * 2021-03-19 2024-05-23 Sunshine Lake Pharma Co., Ltd. Uses of fgf21 polypeptides and fusion polypeptides thereof
CN113198002A (zh) * 2021-05-12 2021-08-03 上海交通大学医学院附属第九人民医院 一种用于治疗非酒精性脂肪肝的肝细胞因子bmp9
WO2023280144A1 (zh) * 2021-07-05 2023-01-12 上海翰森生物医药科技有限公司 一种融合蛋白及其医药用途
CN113717269B (zh) * 2021-08-31 2022-04-19 赣江中药创新中心 一种重组的变体fgf21蛋白及其制备方法和应用
WO2023245543A1 (en) * 2022-06-23 2023-12-28 Ampsource Biopharma Shanghai Inc. Uses of fgf21 fusion proteins

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
WO1990002175A1 (en) 1988-08-16 1990-03-08 Novo Nordisk A/S A method of producing polypeptides by culturing eukaryotic cells in the presence of protease inhibitors
US5851800A (en) 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
US20040259780A1 (en) 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
CA2484556A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
AU2004251145C1 (en) 2003-06-12 2011-04-14 Eli Lilly And Company GLP-1 analog fusion proteins
EP1735340A2 (en) * 2004-03-17 2006-12-27 Eli Lilly And Company Glycol linked fgf-21 compounds
EP2126106B1 (en) 2007-02-23 2017-09-06 Sk Chemicals Co., Ltd. Process for producing and purifying factor viii and its derivatives
JP5577243B2 (ja) 2007-05-30 2014-08-20 ポステク アカデミー−インダストリー ファウンデイション 免疫グロブリン融合タンパク質
JP2010535781A (ja) 2007-08-03 2010-11-25 イーライ リリー アンド カンパニー 肥満に対する処置
JOP20190083A1 (ar) * 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
UA105016C2 (uk) 2008-10-10 2014-04-10 Амген Інк. Fgf21 мутанти і їх застосування
WO2010065439A1 (en) * 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
WO2011089170A2 (en) * 2010-01-22 2011-07-28 Novo Nordisk A/S Process for preparing fgf-21 with low degree of o-glycosylation
ES2730800T3 (es) 2009-02-03 2019-11-12 Amunix Pharmaceuticals Inc Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
EP2427207B1 (en) * 2009-05-05 2017-08-16 Amgen, Inc Fgf21 mutants and uses thereof
KR101860572B1 (ko) 2009-05-05 2018-05-24 암젠 인크 Ｆｇｆ２１ 돌연변이체 및 이의 용도
US20120172298A1 (en) 2009-06-11 2012-07-05 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
CN103124562A (zh) * 2010-06-08 2013-05-29 诺沃—诺迪斯克有限公司 Fgf21的类似物和衍生物
EP2595647A1 (en) * 2010-07-20 2013-05-29 Novo Nordisk A/S N-terminal modified fgf21 compounds
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
WO2012093127A2 (en) 2011-01-04 2012-07-12 Universität Zürich Modulators of il-12 and/or il-23 for the prevention or treatment of alzheimer's disease
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
MX2014002260A (es) 2011-08-31 2014-08-18 Amgen Inc Factor de crecimiento de fibroblasto 21 para usar en el tratamiento de diabetes tipo 1.
US9458214B2 (en) 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
CN102558358A (zh) 2011-12-30 2012-07-11 张海涛 人成纤维细胞生长因子21融合蛋白及其突变体的制备与应用
WO2013131091A1 (en) * 2012-03-02 2013-09-06 New York University Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity and related metabolic disorders
TWI513705B (zh) * 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
WO2014130659A1 (en) 2013-02-22 2014-08-28 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US10286078B2 (en) * 2013-09-13 2019-05-14 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
JP6702962B2 (ja) 2014-10-24 2020-06-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改変ｆｇｆ−２１ポリペプチドおよびその使用
ES2920394T3 (es) * 2015-06-23 2022-08-03 Intervet Int Bv Solución de isoxazolina que contiene vitamina E para usar con agua potable desinfectada
SI3368554T1 (sl) 2015-10-28 2020-10-30 Yuhan Corporation Dolgo-delujoči FGF21 fuzijski proteini in farmacevtski sestavek, ki obsega le-te
RU2741345C2 (ru) 2015-10-28 2021-01-25 Юхан Корпорейшн Белки с двойной функцией и содержащая их фармацевтическая композиция
CN105288592A (zh) 2015-11-02 2016-02-03 哈尔滨博翱生物医药技术开发有限公司 成纤维细胞生长因子-21成熟肽在制备肝纤维化治疗药物中的应用
AU2017358289A1 (en) 2016-11-10 2019-06-20 Yuhan Corporation Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
JP7181886B2 (ja) 2017-03-14 2022-12-01 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 免疫グロブリンのＦｃ部分を含む二重標的融合タンパク質
JP7191850B2 (ja) 2017-04-21 2022-12-19 ユーハン・コーポレイション デュアル機能タンパク質およびその誘導体を生産するための方法

Also Published As

Publication number Publication date
EP3368554A1 (en) 2018-09-05
AU2016346864A1 (en) 2018-05-10
CA3003109A1 (en) 2017-05-04
KR20170049319A (ko) 2017-05-10
CN108290937B (zh) 2022-03-08
SI3368554T1 (sl) 2020-10-30
US20220002367A1 (en) 2022-01-06
HUE051036T2 (hu) 2021-01-28
HK1257375A1 (zh) 2019-10-18
JP7453943B2 (ja) 2024-03-21
JP2021184727A (ja) 2021-12-09
EP3368554B1 (en) 2020-08-05
PT3368554T (pt) 2020-09-10
RS60725B1 (sr) 2020-09-30
JP2018534929A (ja) 2018-11-29
RU2741087C2 (ru) 2021-01-22
EP3368554A4 (en) 2019-06-19
DK3368554T3 (da) 2020-08-31
JP7303629B2 (ja) 2023-07-05
RU2018119141A (ru) 2019-12-02
AU2021204115A1 (en) 2021-07-15
MX2018005194A (es) 2018-07-06
BR112018008676A2 (pt) 2018-11-27
ES2815540T3 (es) 2021-03-30
AU2016346864B2 (en) 2021-03-18
LT3368554T (lt) 2020-09-25
US11142557B2 (en) 2021-10-12
CN108290937A (zh) 2018-07-17
HRP20201392T1 (hr) 2020-11-27
WO2017074117A1 (en) 2017-05-04
US20180305428A1 (en) 2018-10-25
EP3744731A1 (en) 2020-12-02
ZA201802002B (en) 2019-05-29
RU2018119141A3 (el) 2020-03-24

Similar Documents

Publication Publication Date Title
CY1123307T1 (el) Πρωτεϊνες συγχωνευσης fgf21 μακρας δρασης και φαρμακευτικες συνθεσεις που τις περιλαμβανουν
MX2018005193A (es) Proteinas de doble funcion y composicion farmaceutica que comprende las mismas.
CY1123657T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
MX2019012081A (es) Proteina de fusion del factor de crecimiento 21 de fibroblastos humanos (hfgf21), metodo de preparacion de la misma y su uso.
EA201790568A1 (ru) Применение двойного агониста рецепторов glp-1/глюкагона пролонгированного действия для лечения неалкогольной жировой болезни печени
MY187047A (en) Selective pyy compounds and uses thereof
SG10202007194PA (en) Multispecific antigen-binding molecules having blood coagulation factor viii (fviii) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ing
GT201600263A (es) Ácidos grasos novedosos y su uso en la conjugación con biomoléculas
EA201590525A1 (ru) Слитые белки для лечения метаболического синдрома
BR112018004536A2 (pt) peptídeos de endereçamento à cartilagem
EA201890343A1 (ru) Быстродействующие инсулиновые композиции
CL2012000092A1 (es) Compuestos derivados de piridina y pirazina o una sal de los mismos, moduladores de proteina quinasa cdk9; composicion farmaceutica que los comprende, util para el tratamiento del cancer, hipotrofia cardiaca, vih y enfermedades inflamatorias.
BR112018077457A2 (pt) composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
EA201991207A1 (ru) Новые агонисты tnfr и их применение
BR112018004078A2 (pt) composições farmacêuticas, usos de proteinas de fusão e métodos para tratar câncer e para inibir a metástase em um indivíduo
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
EA201690159A1 (ru) Способы и композиции для лечения рака
BR112016026811A2 (pt) formulação de anticorpo
AR103544A1 (es) FORMULACIONES FARMACÉUTICAS PARA ANTICUERPOS ANTI-TNF-a
CY1124493T1 (el) Υγρη φαρμακευτικη συνθεση
MA32622B1 (fr) Derives de carbonate de quinuclidine et composition medicinale les comprenant
WO2017041001A3 (en) Insulin immunoglobulin fusion proteins
BR112017001093A2 (pt) formulação aquosa compreendendo paracetamol e ibuprofeno